%0 Journal Article %J J Matern Fetal Neonatal Med %D 2012 %T Lutein and zeaxanthin supplementation in preterm infants to prevent retinopathy of prematurity: a randomized controlled study. %A Dani, Carlo %A Lori, Ilaria %A Favelli, Federica %A Frosini, Saverio %A Messner, Hubert %A Wanker, Petra %A De Marini, Sergio %A Oretti, Chiara %A Boldrini, Antonio %A Massimiliano, Ciantelli %A Bragetti, Patrizia %A Germini, Cristiana %K Antioxidants %K Drug Administration Schedule %K Drug Combinations %K Female %K Humans %K Infant, Newborn %K Infant, Premature %K Logistic Models %K Lutein %K Male %K Retinopathy of Prematurity %K Risk Factors %K Treatment Outcome %K Xanthophylls %K Zeaxanthins %X

OBJECTIVES: Lutein and its isomer zeaxanthin (L/Z) function in the eye as antioxidant agents and blue-light filters. Our aim was to evaluate whether their administration could help decrease the occurrence of retinopathy of prematurity (ROP) in preterm infants.

METHODS: Infants with gestational age ≤32 weeks were randomly assigned to receive a daily dose of L/Z (0.14 + 0.006 mg) or placebo until discharge.

RESULTS: ROP occurrence was similar in the L/Z (11/58; 19%) and placebo (15/56; 27%) groups, as the occurrence of ROP at each stage and the need of eye surgery.

CONCLUSION: L/Z supplementation was ineffective in preventing ROP in preterm infants and did not affect the outcome at discharge of our patients.

%B J Matern Fetal Neonatal Med %V 25 %P 523-7 %8 2012 May %G eng %N 5 %1 http://www.ncbi.nlm.nih.gov/pubmed/22003960?dopt=Abstract %R 10.3109/14767058.2011.629252